勃林格殷格翰能倍乐进入医保了吗？

Is Boehringer Ingelheim Respimat included in health insurance? According to Medical Partner Travel, in July 2018, Sihehua® Respimat® (tiotropium bromide/olodaterol inhalation spray) was officially approved by the China Food and Drug Administration for long-term maintenance treatment of patients with chronic obstructive pulmonary disease (including chronic bronchitis and emphysema). Currently, this drug is included in the Class B drugs in the medical insurance catalog, but medical insurance reimbursement standards vary from place to place, and reimbursement needs to meet certain restrictions. Patients who do not have medical insurance can choose the overseas version of Boehringer Ingelheim Respimat. It is understood that the current price is relatively low at about 170 US dollars per box. Patients in need can go abroad to buy or obtain the medicine through domestic professional overseas medical service organizations (such as Medical Companion Travel), and have it shipped directly to their homes, ensuring authenticity.

Dual-branched Silihua Respimat is developed on the basis of tiotropium bromide (Silivar). Sihehua adds a new long-acting β2 receptor agonist, olodaterol, to tiotropium bromide. The two drugs can achieve complementary mechanisms and synergistic effects to further improve the airflow limitation of COPD, thereby helping patients breathe more smoothly. A large amount of clinical research data proves that Sihehua Respimat can provide patients with COPD with better curative effects than Sliva, including controlling COPD symptoms, reducing the risk of acute exacerbation, and improving patients' quality of life, and its safety is equivalent to Sliva.

It is developed and produced by Boehringer Ingelheim, one of the top 20 pharmaceutical companies in the world. It is headquartered in Ingelheim, Germany, and has 145 subsidiaries and approximately 47,500 employees worldwide. The company was founded in 1885 and is a family-owned business. The company has always been committed to the research, development, production and promotion of new drugs with high therapeutic value for humans and animals. Boehringer Ingelheim's current total investment in China exceeds 300 million euros. The company's management headquarters is located in Shanghai, with business spread across the country and approximately 4,500 employees.

Recommended related articles:

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.